Dr. Tripathy on Neoadjuvant Agents for HER2+ Breast Cancer
November 16th 2016Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses agents that are available and in development in the neoadjuvant setting as treatments for patients with HER2-positive breast cancer.
Novel Antibody-Drug Conjugate Could Become First Targeted Therapy Approved in TNBC
November 15th 2016Findings from a highly anticipated, randomized, phase II trial could possibly pave the path for the FDA approval of the first targeted therapy for patients with triple-negative breast cancer, explains Linda T. Vahdat, MD.
Dr. Vokes on Nivolumab, Pembrolizumab Approvals in Head and Neck Cancer
November 12th 2016Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses the FDA approvals of the PD-L1 inhibitors nivolumab (Opdivo) and pembrolizumab (Keytruda) for the treatment of patients with head and neck cancer.
Immunotherapy Combo Regimens on Horizon in Lymphoma
November 12th 2016Nivolumab (Opdivo) may be the only checkpoint inhibitor that is approved by the FDA as a treatment of patients with Hodgkin lymphoma, but other immunotherapies—alone and in combination with other novel agents—are emerging in other indications.
Dr. Dreicer on Combination Trials With Radium-223 in mCRPC
November 12th 2016Robert Dreicer, MD, associate director for Clinical Research and deputy director of the University of Virginia Cancer Center, discusses the potential of combination regimens involving radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer (mCRPC).
Patient Selection Critical to Optimizing Neoadjuvant Chemo in Ovarian Cancer
November 11th 2016As a treatment of patients with advanced ovarian cancer, evidence has shown that neoadjuvant chemotherapy has reduced mortality and improved quality of life. However, oncologists are still challenged at how to deploy this treatment approach in clinical practice.
Dr. Marshall on Challenges With Cancer Moonshot Initiative
November 10th 2016John L. Marshall, MD, chief, Division of Hematology/Oncology, Georgetown University Hospital, discusses potential obstacles ahead with the Cancer Moonshot Initiative following the results of the 2016 United States presidential election.
Dr. Venook on Distinguishing Molecular Features in CRC
November 10th 2016Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses evolving treatment strategies for patients with colorectal cancer, with regards to molecular features such as sidedness.
Dr. Mauro on Selecting Therapies for Patients With CML
January 15th 2016Michael J. Mauro, MD, hematologist, leader of the Myeloproliferative Neoplasms Program, Leukemia Service at Memorial Sloan Kettering Cancer Center, discusses how to best select therapies for patients with chronic myeloid leukemia.
Dr. Burtness on Emerging Immunotherapies in Head and Neck Cancer
January 12th 2016Barbara A. Burtness, MD, professor of Medicine (Medical Oncology), clinical research program leader, Head and Neck Cancers Program, co-director, Developmental Therapeutics Research Program, Yale Cancer Center, discusses emerging immunotherapies and ongoing clinical trials in head and neck cancer.
Dr. Waxman on Advancements in Acute Promyelocytic Leukemia
November 11th 2015Samuel Waxman, MD, Distinguished Service Professor of Medicine, Hematology and Medical Oncology, Distinguished Service Professor of Oncological Sciences, Mount Sinai Health System, discusses advancements in treating patients with acute promyelocytic leukemia.
Dr. John Marshall on the Importance of Molecular Profiling in Colorectal Cancer
November 10th 2015John Marshall, MD, Chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital, Chief, Division Of Hematology/Oncology, Georgetown University Hospital Associate Director, Clinical Research, Lombardi Comprehensive Cancer Center at Georgetown University Hospital, discusses the importance of molecular testing in colorectal cancer.
BRAF/MEK Combination Highly Effective in Melanoma
Adding the MEK inhibitor trametinib to the BRAF inhibitor dabrafenib significantly improves long-term outcomes while lowering certain adverse events associated with either agent alone for patients with BRAF-mutated metastatic melanoma.
Dr. Weber on Dabrafenib/Trametinib Approval for Melanoma
November 6th 2015Jeffrey S. Weber, MD, PhD, deputy director, Laura and Isaac Perlmutter Cancer Center, co-director of its Melanoma Program and Head of Experimental Therapeutics, NYU Langone Medical Center, discusses the significance of the FDA approval of the combination of dabrafenib and trametinib for patients with unresectable or metastatic melanoma who harbor a BRAF V600E or V600K mutation.
Dr. Philip on Olaratumab for Soft Tissue Sarcoma
November 6th 2015Tony Philip, MD, medical oncologist, Monter Cancer Center of the North Shore-LIJ Cancer Institute, assistant professor of Medicine, Hofstra-North Shore LIJ School of Medicine and NYIT College of Osteopathic Medicine, discusses approved and emerging agents for soft tissue sarcomas.
Targeted Therapies Improve Outcomes in Advanced Thyroid Cancer
The kinase inhibitors sorafenib and lenvatinib have significantly altered the treatment paradigm for patients with advanced radioactive iodine-refractory differentiated thyroid cancer in both older and younger populations.
In Pursuit of Less Toxic Treatments for HPV+ Oropharyngeal Cancers
November 5th 2015While the prognosis remains good for individuals with HPV-positive oropharyngeal cancers, the incidence of these cancers continues to rise, and researchers are currently seeking less intense treatment options that are equally effective but not as toxic for patients.